Skip Navigation



Europace Advance Access published online on June 16, 2008
Europace, doi:10.1093/europace/eun150
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
10/9/1034    most recent
eun150v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ding, L.
Right arrow Articles by Zhang, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ding, L.
Right arrow Articles by Zhang, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Primary prevention of sudden cardiac death using implantable cardioverter defibrillators

Ligang Ding, Wei Hua*, Hongxia Niu, Keping Chen and Shu Zhang

Center of Arrhythmia, Fuwai Cardiovascular Hospital, Peking Union Medical College, Beijing, China

Despite substantial advances in prevention and treatment of cardiovascular diseases, sudden cardiac death (SCD) remains a leading cause of death in industrialized countries. Implantable cardioverter defibrillator (ICD) has been demonstrated to be an attractive option for primary prevention of SCD in high-risk patients. This review discusses the progress in the risk stratification for selecting high-risk patients, highlights the clinical trials of primary prevention for SCD, outlines the efficacy of combined use of cardiac resynchronization therapy with ICD, and analyses the cost-effectiveness issue of this device.

Key Words: Sudden cardiac death, Implantable cardioverter defibrillator, Primary prevention

* Corresponding author. Tel/fax: +86 1088398290. E-mail address: drhua{at}vip.sina.com

Manuscript submitted 16 December 2007. Accepted after revision 19 May 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.